Medtronic plc has announced that the US Food and Drug Administration (FDA) has approved the use of the MiniMed 670G system in patients with type 1 diabetes aged ≥7 years.
This newest system by Medtronic features the company's most advanced SmartGuard technology and most accurate CGM—the Guardian Sensor 3—which work together to automate the delivery of a personalized amount of basal insulin every 5 minutes based on sensor glucose values. The system constantly self-adjusts to help avoid highs and lows, allowing patients to spend more Time in Range (the percentage of time spent in the optimal glycemic range of 70-180 mg/dL). In the US, Medtronic plc is headquartered in Minneapolis, MN.
Medtronic receives FDA approval of new pediatric indication for the MiniMed 670G Hybrid closed loop system in children ages 7-13. [news release]. Minneapolis, MN: Medtronic plc. June 21, 2018. http://newsroom.medtronic.com/phoenix.zhtml?c=251324&p=irol-newsArticle&ID=2355586. Accessed July 6, 2018.
This Week's Must Reads
Breakfast in the Classroom Initiative and Obesity, JAMA Pediatrics; ePub 2019 Feb 25; Polonsky, et al
Must Reads in Diabetes
FDA Approves System for Children with T1D, Medtronic plc news release; 2018 Jun 21
Very Low-Carbohydrate Diet Beneficial for T1D, Pediatrics; ePub 2018 May 7; Lennerz, et al
SSRI/SNRI Antidepressants Increase T2D Risk, JAMA Pediatr; ePub 2017 Oct 16; Brucu, et al
Computer-Automated Diabetes Screening Found Effective , JAMA Pediatr; 2017 Feb 13; Hannon, et al